- Pfizer (PFE +1.5%) has formally completed the acquisition of Trillium Therapeutics (TRIL).
- Pfizer agreed to buy Trillium in a $2.3B deal in late August.
- Trillium has two lead candidates, TTI-622 and TTI-621.
- TTI-622 is enrolling in a phase 1 trial for multiple myeloma and acute myeloid leukemia. TTI-621 is set to begin in phase 2 for peripheral T-cell lymphoma by the end of the year.
- Trillium shares have been delisted from Nasdaq.